Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey
| Autor: | Mar Tintoré, Mattia Fonderico, Bernhard Hemmer, Tobias Derfuss, B. Stankoff, Emilio Portaccio, Maria Pia Amato, Krzysztof Selmaj |
|---|---|
| Přispěvatelé: | Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Munich Cluster for systems neurology [Munich] (SyNergy), Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM)-Ludwig-Maximilians-Universität München (LMU), University Hospital Basel [Basel], Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Warmia and Mazury [Olsztyn], Centre d'Esclerosi Múltiple de Catalunya (CemCat), Technical University of Munich (TUM)-Ludwig-Maximilians-Universität München (LMU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de neurologie 1 [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU) |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Telemedicine 2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) [SDV]Life Sciences [q-bio] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) medicine.disease_cause Coronavirus disease-19 Multiple sclerosis 03 medical and health sciences Multiple Sclerosis Relapsing-Remitting 0302 clinical medicine medicine Humans 030212 general & internal medicine Intensive care medicine Coronavirus access to care Fingolimod Hydrochloride SARS-CoV-2 business.industry disease-modifying treatment COVID-19 medicine.disease 3. Good health Neurology telemedicine Neurology (clinical) business Original Research Papers Immunosuppressive Agents 030217 neurology & neurosurgery |
| Zdroj: | Multiple Sclerosis Journal Multiple Sclerosis Journal, SAGE Publications, 2021, pp.135245852110053. ⟨10.1177/13524585211005339⟩ Multiple Sclerosis (Houndmills, Basingstoke, England) |
| ISSN: | 1477-0970 1352-4585 |
| DOI: | 10.1177/13524585211005339 |
| Popis: | Background: The spread of Coronavirus disease-19 (COVID-19) poses unique challenges in the management of people with multiple sclerosis (PwMS). Objectives: To collect data about the impact of COVID-19 emergency on access to care for PwMS and on MS treatment practices. Methods: Between March and July 2020, the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) promoted an online survey covering patient access to care, management of relapses and visits, disease-modifying therapy (DMT) and experience with COVID-19. Results: Three-hundred and sixty neurologists from 52 countries (68% from Europe) completed the survey. 98% reported COVID-19-related restrictions. Telemedicine was adopted to overcome the limited access to care and was newly activated (73%) or widely implemented (17%). 70% reported changes in DMT management. Interferons and glatiramer were considered safe. Dimethyl fumarate, teriflunomide and fingolimod were considered safe except for patients developing lymphopenia. No modifications were considered for natalizumab in 64%, cladribine in 24%, anti-CD20 in 22% and alemtuzumab in 17%; 18% (for alemtuzumab and cladribine) and 43% (for anti-CD20) considered postponing treatment. Conclusion: The ECTRIMS survey highlighted the challenges in keeping standards of care in clinical practice. Telemedicine clearly needs to be implemented. Gathering data on DMT safety will remain crucial to inform treatment decisions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|